Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity
Aspire Biopharma (NASDAQ:ASBP) announced delivery of two million units of its flagship caffeine supplement BUZZ BOMB™ on January 22, 2026, and strategic inventory of 100,000 20-packs now available to meet demand.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aspire Biopharma (NASDAQ:ASBP) announced delivery of two million units of its flagship caffeine supplement BUZZ BOMB™ on January 22, 2026, and strategic inventory of 100,000 20-packs now available to meet demand. The rollout includes a modernized brand identity, redesigned high-impact packaging, an emphasis on 50mg precise dosing and near-instant sublingual absorption, and a new e-commerce storefront. Aspire plans an aggressive growth push via expanded digital marketing, influencer partnerships, DTC optimization, and evaluation of retail and wholesale channels to scale the consumer business.
Positive
- 2,000,000 BUZZ BOMB units delivered to support commercialization
- 100,000 20-pack inventory positioned for immediate availability
- 50mg precise per-stick dosing emphasized for product consistency
- New e-commerce storefront plus targeted digital and influencer marketing
Negative
- None.
Details
News Market Reaction – ASBP
On Jan 22, the day this news came out, ASBP closed 5.24% below the previous close.
Data tracked by StockTitan Argus for the Jan 22 session.
Key Figures
- BUZZ BOMB units
- 2,000,000 units
- Inventory delivery for flagship caffeine supplement
- BUZZ BOMB packs
- 100,000 20-packs
- Strategic inventory configuration for consumer launch
- Caffeine dose
- 50 mg
- Per-serving precise dosing in BUZZ BOMB product
- Stock plan share limit
- 4,890,000 shares
- 2024 Stock Incentive Plan capacity per 8-K on Jan 15, 2026
- Debt exchanged
- $1,750,000
- Outstanding debt swapped into common stock per Jan 6, 2026 8-K
- Q3 2025 net revenue
- $1,941
- Quarter ended September 30, 2025
- Q3 2025 net loss
- $1,850,493
- Quarter ended September 30, 2025
- Equity line capacity
- $100,000,000
- New equity line of credit with Arena per Nov 14, 2025 8-K
Historical Context
-
Filed provisional patent for rapid-onset sublingual alprazolam formulation.
-
1-for-40 reverse split to address Nasdaq minimum bid requirement.
-
Pre-IND FDA meeting backed a 505(b)(2) NDA path for OTASA.
-
Named elite ultra-runner Ashley Paulson as BUZZ BOMB brand ambassador.
-
Nasdaq panel granted limited extension to regain bid price and equity compliance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
sublingual medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Strategic inventory of 100,000 20-packs now available to meet increasing demand for rapid-onset sublingual caffeine technology
ESTERO, FL / ACCESS Newswire / January 22, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP), a leader in innovative patent-pending sublingual delivery technologies, today announced it has taken delivery of two million units of its flagship caffeine supplement, BUZZ BOMB™.
This delivery marks a critical milestone in Aspire's commercialization strategy, introducing a comprehensive brand relaunch and redesigned packaging. The new aesthetic is engineered for high-impact shelf presence and digital engagement, emphasizing the product's core advantages: nearly instant energy, precise 50mg dosing, and the convenience of sublingual absorption.
BUZZ BOMB™ Newly Designed Packaging
Unlike traditional energy drinks or pills, BUZZ BOMB™--a dry powder sprinkled under the tongue from a single-serving stick pack--utilizes a proprietary sublingual format that delivers pure caffeine quickly without the hassle of mixing with water, without drinking typical caffeine sources like energy drinks, coffee, or soda.
"This significant inventory delivery of BUZZ BOMB™ is expected to support the launching of our expanded consumer strategy," said Kraig Higginson, Interim CEO of Aspire Biopharma. "By combining our new production capacity with a modernized brand identity, BUZZ BOMB™ is uniquely positioned to scale. Together with our new online e-commerce website and refreshed packaging design, BUZZ BOMB™ is primed to capture significant market share by introducing our revolutionary sublingual technology to a wider audience."
To drive growth following this delivery, Aspire plans to launch an aggressive marketing campaign featuring:
Expanded Digital Marketing: Targeted campaigns across high-traffic social platforms.
Influencer Partnerships: Collaborations with performance-focused creators in the fitness and healthy lifestyle sectors.
DTC Optimization: Streamlined purchasing via the BUZZ BOMB™ official storefront.
The Company is concurrently evaluating new retail partnerships and wholesale distribution channels to maximize the reach of the refreshed 20-pack configurations.
About BUZZ BOMB™
BUZZ BOMB™ is a proprietary sublingual caffeine supplement developed by Aspire Biopharma that features 50mg of caffeine and is currently offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha). Designed for athletes, professionals, and the everyday person needing a rapid cognitive boost, BUZZ BOMB™ provides a precise dose of caffeine that bypasses the GI tract for faster onset and smoother energy. To learn more about BUZZ BOMB™, or purchase product online, please visit https://buzzbombcaffeine.com. New flavors are under development and will be released in the coming months.
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs and supplements to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma's delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.
For more information, please visit www.aspirebiolabs.com
Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.